Evercore ISI raised the firm’s price target on Abbott to $124 from $120 and keeps an Outperform rating on the shares. In MedTech, utilization remains positive into Q3 and the capex outlook into the next year remains “healthy,” says Evercore. In life science tools, bioprocess trends for are on track for improvement in the second half, but the debate is around the instrument outlook and China stimulus given the recent run in stocks in the space, the analyst tells investors in MedTech and Tools Q3 preview.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott Labs (NYSE:ABT) Goes to Trial Over Baby Formula
- Abbott pricing in higher NEC liability than expected, says Jefferies
- Five Below downgraded, DoorDash upgraded: Wall Street’s top analyst calls
- Abbott initiated with an Overweight at Piper Sandler
- Medtronic CEO: We’ve pivoted from a tech perspective